Comparison Workspace
Program Compare
Compare up to 6 HearScape records side by side across ownership, modality, stage, evidence, populations, trials, source support, and review notes.
1 Selected Records
URL-shareable comparison set.
| Field | FX-322 by Frequency Therapeutics Frequency Therapeutics |
|---|---|
| Organization | Company: Frequency Therapeutics |
| Program Type | Therapeutic |
| Modality | Regenerative Medicine |
| Stage / Status | Phase 2 / Discontinued |
| Review Status | checked · company |
| Confidence | 96% |
| Target / Gene | — |
| Route / Mode | Intratympanic injection |
| Indications | Hearing Loss; Sensorineural Hearing Loss; Noise-Induced Hearing Loss; Sudden Sensorineural Hearing Loss |
| Population Tags | adult |
| Geography | United States |
| Trials | |
| Source Support | 3 structured sources · 3 URL-backed · company, clinicaltrials |
| Last Reviewed | 2026-05-31 |
| Data Checks | No data flags |
| Mechanism | Intratympanic small-molecule combination was designed to activate cochlear progenitor cells and regenerate sensory cells needed for hearing. |
| Notes | Field-shaping hearing-regeneration program that drove broad investor and scientific attention before a negative Phase 2b readout ended the franchise. Generated dose-arm rows from FX-322 trials are treated as covered by this canonical program record, not as separate programs. |